Search Results

Study Shows CAS Using Mo.Ma Cerebral Protection Device in Octogenarians to Be Safe

July 1, 2010—In Catheterization and Cardiovascular Interventions, Antonio Micari, MD, et al have published findings from a multicenter prospective registry that sought to show that carotid artery stenting (CAS) in octogenarians is safe and effective if performed in high-volume centers by experienced operators (2010;76:9–15).

Medtronic's In.Pact Admiral Paclitaxel-Coated Balloon Evaluated at 2 Years in DEB SFA-LONG Study

September 20, 2016—Antonio Micari, MD, presented results from the DEB SFA­-LONG study during the second Late-Breaking Trials session at VIVA 16, the 14th annual Vascular InterVentional Advances meeting, which is sponsored by VIVA Physicians, Inc. and held September 18–22, 2016 at the Wynn Las Vegas in Las Vegas, Nevada.

Two-Year Results Reported From IN.PACT Global Study of Medtronic's In.Pact Admiral DCB in Femoropopliteal Lesions

May 30, 2018—Two-year results from the IN.PACT Global study were published by Antonio Micari, MD, et al in Journal of the American College of Cardiology (JACC): Cardiovascular Interventions (2018;11:945–953).

One-Year Data Published for Medtronic Invatec's In.Pact Admiral Paclitaxel-Eluting Balloon

March 20, 2012—Twelve-month results from a multicenter Italian registry evaluating the use of a paclitaxel-eluting balloon (PEB) for treatment of femoropopliteal arterial disease were published by Antonio Micari, MD, et al in the Journal of the American College of Cardiology: Cardiovascular Interventions (2012;5:331–338).

Two-Year Independent Registry Results Support Medtronic's In.Pact Admiral Paclitaxel-Eluting Balloon for Femoropopliteal Artery Disease

March 25, 2013—Two-year data from an independent, prospective, multicenter registry aimed at assessing outcomes of femoropopliteal angioplasty with a paclitaxel-eluting balloon (PEB) (In.Pact Admiral, Medtronic, Inc., Minneapolis, MN) were recently published by Antonio Micari, MD, et al in the Journal of the American College of Cardiology: Cardiovascular Interventions (2013;6:282–289).In the study, 105 consecutive patients with Rutherford class 2 to 4 disease caused by femoropopliteal lesions ≤ 15 mm long and with 3- to 7-mm reference vessel diameters were enrolled.

Medtronic Invatec's DEBs Show Promise for Treating Lower Limb Arteries

November 9, 2011—According to data presented at the annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in San Francisco, use of drug-eluting balloons resulted in positive 1-year outcomes in patients with femoropopliteal arterial disease and diabetic patients with critical limb ischemia in below-the-knee (BTK) vessels.

Medtronic Begins IN.PACT BTK Study in Europe

March 9, 2017—Medtronic plc announced the commencement of the IN.PACT BTK study in Europe to evaluate the effectiveness of a drug-coated balloon (DCB) in patients with below-the-knee (BTK) peripheral artery disease (PAD). The European study will evaluate the company's 0.014-inch In.Pact paclitaxel-coated percutaneous transluminal angioplasty (PTA) balloon catheter, which uses In.Pact Admiral drug-coating technology.

Medtronic Announces Plans for IN.PACT Global SFA Drug-Eluting Balloon Study

April 17, 2012—Medtronic, Inc. (Minneapolis, MN) announced that it will be commencing the IN.PACT Global superficial femoral artery (SFA) clinical study.

Studies Evaluate Medtronic's In.Pact Admiral DCB in Long Lesions

May 20, 2015—Medtronic plc announced the presentation of new clinical data from two different studies, the IN.PACT Global Study's long lesion imaging cohort and the DEB SFA-LONG Study, showing that the company’s In.Pact Admiral drug-coated balloon (DCB) successfully treated long lesions in the superficial femoral and popliteal arteries.

9-Month Data Presented From IN.PACT BTK Feasibility Study of Medtronic's In.Pact DCB to Treat CLI

October 18, 2020—Medtronic announced the first results from IN.PACT BTK, a feasibility study assessing the safety and effectiveness of the company's In.Pact 0.014 drug-coated balloon (DCB) in critical limb ischemia (CLI) patients with chronic total occlusion (CTO) in the infrapopliteal arteries.

Abbott Vascular's Absorb Bioresorbable Vascular Scaffold Studied for BTK Treatment

August 30, 2016—In 12-month clinical and imaging follow-up, the Absorb everolimus-eluting bioresorbable vascular scaffold (Abbott Vascular) demonstrated excellent safety, patency, and freedom from target lesion revascularization for the treatment of below-the-knee (BTK) arteries, concluded Ramon L. Varcoe, MBBS, et al in Journal of the American College of Cardiology (JACC): Cardiovascular Interventions (2016;9:1721–1728). 

JACC Patient-Level Analysis of Medtronic DCB Studies Concludes That Mortality Is Not Correlated With Paclitaxel Exposure

January 31, 2019—Peter A. Schneider, MD, et al conducted a patient-level analysis of data from several independently adjudicated prospective studies involving Medtronic drug-coated balloons (DCBs). The findings were published online ahead of print in Journal of the American College of Cardiology (JACC).